STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF

重组 RHUMAB VEGF 的安全性和药代动力学特征研究

• 批准号: 6117854
• 负责人: Michael Gordon
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117854
• 关键词: clinical research; clinical trial phase I; drug screening /evaluation; human subject; monoclonal antibody; neoplasm /cancer chemotherapy; pharmacokinetics; recombinant proteins; vascular endothelial growth factors

rhuMAb VEGF is an experimental humanized monoclonal antibody produced by Genentech using recombinant DNA technology. Antibodies are proteins that can protect the body from foreign invaders, such as bacteria and viruses. rhuMAb VEGF is a monoclonal antibody to vascular endothelial growth factor (VEGF), which is present in a wide variety of normal tissues but is produced in excess by most solid cancers (tumors)> In the setting of cancer, VEGF promotes the growth of blood vessels that bring nutrients to the tumor cells. In laboratory studies, rhuMAb VEGF inhibits the growth of many different cancers in animals by blocking the effects of VEGF.

Rhumab VEGF是一种实验性人性化的单克隆抗体，该抗体由 Genentech使用重组DNA技术。 抗体是蛋白质 可以保护身体免受外国入侵者的侵害，例如细菌和病毒。 Rhumab VEGF是一种对血管内皮生长因子的单克隆抗体 （VEGF），它存在于多种正常组织中，但 大多数固体癌（肿瘤）>在 癌症，VEGF促进了使营养成分的血管生长 肿瘤细胞。 在实验室研究中，Rhumab VEGF抑制了生长 通过阻断VEGF的影响，动物中许多不同的癌症的作用。